Prostate Health Market

Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026

Report Code: PH 8020 Dec, 2021, by marketsandmarkets.com

[99 Pages Report] The global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, increase in prevalence of prostate cancer, surge in demand for hormone therapy drugs, emerging therapies for prostate cancer and increasing incidence of prostatitis.

The Prostate health market is fragmented, with several players offering branded and generic medication for Prostate health.

Prostate Health Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the Global Prostate Health Market

The prostate health market witnessed a loss of business, and the trend continued till late December 2020. Unfavorable changes in regulations and guidelines are hindering the growth of this industry. Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that cancer patients are at greater risk of contracting the coronavirus infection than healthy adults. Thus, prostate care, diagnostic tests, and surgical treatments in hospitals are severely restricted or postponed at hospitals and cancer care centers. This is expected to cause disturbances in the prostate health market. Owing to the factors above, caregivers and hospitals are anticipated to witness delays in elective surgeries and screening procedures. However, the market has gradually increased from the second half of 2020 due to the rise in the number of oncology appointments, prostate cancer therapies among others resulting from efforts to clear backlogs and new cases and fully re-opened healthcare services.

Drivers: Growing prevalence of prostate cancer and BPH

Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 showed that nearly 7,600,000 patients were diagnosed with BPH in 2010, which increased by ~1.2 million in 2017. This represents an annual growth of about 7% and a total increase of 58% from 2010. Obesity and Benign Prostatic Hyperplasia (BPH) are closely associated. According to the Journal of Global Health Reports published in 2019, nearly 37.1% of men aged 60 years and older in the US were classified as obese. Studies reveal that the prevalence of obesity generally increases among men with progressing age, leading to BPH. Obesity leads to several mechanisms such as enhanced sympathetic nervous activity, altered endocrine status, increased intra-abdominal pressure, increased inflammation process, and oxidative stress, which are favorable conditions for the development of BPH. The prevalence of prostate cancer rises with an increase in age. Prostate cancer is the most common category of cancer among men. According to the American Cancer Society’s estimates for prostate cancer in 2021, about 248,530 new cases and 34,130 deaths occurred in 2020 due to prostate cancer in the US. The prostate cancer phase III pipeline is diverse and comprises molecules in approved drug classes as well as drugs with novel mechanisms of action, including radioligands targeted to prostate-specific membrane antigen (PSMA), kinase inhibitors, and immune checkpoint inhibitors.

Restraints: Side effects associated with BPH medications

While drugs and surgery can treat Benign Prostatic Hyperplasia (BPH), both methods are associated with significant side effects. Medicines commonly used to treat BPH consist of alpha blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes. Common side effects of alpha blockers include orthostatic hypotension, dizziness, retrograde ejaculation, and rhinitis. Dizziness and orthostatic hypotension are of increased concern among the elderly as they can cause important morbidities such as falls and subsequent injuries.

Finasteride and Dutasteride (among other 5-ARIs) convert testosterone to dihydrotestosterone. These drugs also decrease the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, and reduced libido and ejaculate volume.

Opportunities: Emerging Economics

Emerging economies (such as China, India, Brazil, and Mexico) are projected to offer significant growth opportunities to market players in the coming years. Factors such as the presence of a large target patient population, rising healthcare expenditure, growing awareness among physicians, and significant increase in the geriatric population are expected to boost the demand for prostate health methods across these countries.

The Asia Pacific is home to a large and rapidly increasing patient population for benign prostatic hyperplasia. Moreover, the proportion of geriatric individuals (who are at a higher risk for these target indications) in the overall population is expected to grow sharply in the region, especially in Japan, China, South Korea, Hong Kong, and Taiwan (Source: US Census Bureau). Considering these factors, prominent and emerging product manufacturers in the prostate health market are progressively focusing on expanding their businesses across emerging Asia Pacific countries.

Challenges: Low awareness regarding prostate health among men

Benign Prostatic Hyperplasia (BPH) is mostly mistaken as an untreatable part of aging rather than a condition that can be treated by visiting the urologist’s office. The low awareness about the signs and symptoms of BPH may lead to many men being left undiagnosed, which may further increase the damage caused to the prostate.

“In 2020, prostate Cancer segment accounted for the largest share of the prostate health market, by disease type”

Based on disease indication, the prostate health market is bifurcated into prostate cancer, benign prostate hyperplasia, and prostatitis. Prostate cancer accounted for the largest share in the prostate health market in 2020. Typically, hormone therapy is considered an efficient option as the first line of treatment for prostate cancer. Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options. Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted extensively for the treatment of prostate cancer in the near future.

“North America is the largest regional market for prostate health market”

The global prostate health market is segmented into five major regions— five six regions—North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2020, North America accounted for the largest share of the prostate health market. The North American prostate health market's growth can be attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers.

Prostate Health Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Market size for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

By Disease Indication & By Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Companies covered

The major market players include are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players

By Disease Indication

  • Prostate Cancer
    • AR Directed Therapies
    • Hormone ADT
    • Cytotoxic Agents
    • PARP Inhibitors
    • Others
  • Benign Prostate Hyperplasia
    • Alpha Blockers
      • Alfuzosin
      • Doxazosin
      • Tamsulosin
      • Silodosin
      • Other Alpha Blockers
    • 5 Alpha Reductase
      • Finasteride
      • Dutasteride
    • Others
  • Prostatitis
    • Prescription
    • Over the counter

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • RoE
  • Asia
    • Japan
    • China
    • India
    • RoAPAC
  • Latin America
  • Middle East & Africa

Recent Developments

  • In March 2022, Lantheus Holdings, Inc. (US) collaborated with Novartis AG (Switzerland) to include PYLARIFY (piflufolastat F18) in prostate cancer clinical trials with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to support prostate cancer clinical development.
  • In March 2022, Novartis AG (Switzerland) received approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) by FDA for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
  • In January 2021, Pharex Tamsulosin for the treatment of benign prostatic hyperplasia was introduced by PHAREX Health Corporation (Philippines) in collaboration with the Philippine Urological Association (PUA).
  • In October 2020, Israeli medical device manufacturer Butterfly Medical raised USD 7 million in a Series B round to develop an anatomically shaped nitinol implant positioned in the prostatic urethra to relieve BPH symptoms
  • In 2020, Asahi Kasei Pharma (Japan) obtained drug approval in China for Flivas (naftopidil), an agent for treating dysuria associated with BPH.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 17)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 LIMITATIONS OF THE CURRENT EDITION OF THE REPORT

2 RESEARCH METHODOLOGY (Page No. - 21)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.1.2.1 Key data from primary sources
    2.2 MARKET SIZE ESTIMATION
           FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 BOTTOM-UP APPROACH
           2.2.2 GROWTH FORECAST
           2.2.3 TOP-DOWN APPROACH
                    FIGURE 4 PROSTATE HEALTH MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 MARKET DYNAMICS (Page No. - 28)
    3.1 MARKET DYNAMICS
           FIGURE 6 PROSTATE HEALTH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           3.1.1 DRIVERS
                    3.1.1.1 Increasing prevalence of benign prostatic hyperplasia
                               FIGURE 7 SHARE OF THE MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)
                    3.1.1.2 Increasing obesity
                    3.1.1.3 Investments, funds, and grants for research in BPH treatment
                    3.1.1.4 Rising prevalence of prostate cancer
                    3.1.1.5 Increasing demand for hormone therapy drugs
                    3.1.1.6 Emerging therapies for prostate cancer
                               TABLE 1 SELECT THERAPIES IN THE PHASE III PIPELINE FOR PROSTATE CANCER
           3.1.2 RESTRAINTS
                    3.1.2.1 Side-effects associated with BPH medications
                               TABLE 2 SIDE-EFFECTS OF BPH DRUGS
           3.1.3 OPPORTUNITIES
                    3.1.3.1 Emerging markets
                    3.1.3.2 Promising product pipeline
                               TABLE 3 PIPELINE DRUGS
           3.1.4 CHALLENGES
                    3.1.4.1 Low awareness regarding prostate health among men
                    3.1.4.2 Product recalls in the prostate health market
                               TABLE 4 PRODUCT RECALLS IN THE PROSTATE HEALTH MARKET

4 PROSTATE HEALTH MARKET, BY DISEASE TYPE (Page No. - 35)
    4.1 INTRODUCTION
           TABLE 5 PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
    4.2 PROSTATE CANCER
           TABLE 6 PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 7 PROSTATE CANCER MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.2.1 AR-DIRECTED THERAPIES
                    4.2.1.1 AR-directed therapies are expected to remain the dominant drug class for the treatment of prostate cancer
                               TABLE 8 AR-DIRECTED THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.2.2 HORMONE ADT
                    4.2.2.1 ADT is the most common form of hormonal treatment
                               TABLE 9 HORMONAL ADT MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.2.3 CYTOTOXIC AGENTS
                    4.2.3.1 Newer cytotoxic agents are being studied in prostate cancer with the goal of achieving FDA approvals
                               TABLE 10 CYTOTOXIC AGENTS MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.2.4 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
                    4.2.4.1 PARP inhibitors are expected to be the leading drug class for the treatment of prostate cancer
                               TABLE 11 PARP INHIBITORS MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.2.5 OTHER THERAPIES
                    TABLE 12 OTHER THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)
    4.3 BENIGN PROSTATIC HYPERPLASIA
           TABLE 13 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
           TABLE 14 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.3.1 ALPHA BLOCKERS
                    TABLE 15 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 16 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018–2026 (USD MILLION)
                    4.3.1.1 Tamsulosin
                               4.3.1.1.1 Tamsulosin has been prescribed for BPH since 2000
                               TABLE 17 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                    4.3.1.2 Silodosin
                               4.3.1.2.1 Benefits of silodosin and the launch of generics to support market growth
                               TABLE 18 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                    4.3.1.3 Alfuzosin
                               4.3.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent
                               TABLE 19 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                    4.3.1.4 Doxazosin
                               4.3.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since
                               TABLE 20 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
                    4.3.1.5 Other alpha blockers
                               TABLE 21 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.3.2 5-ALPHA REDUCTASE INHIBITORS
                    TABLE 22 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 23 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION)
                    4.3.2.1 Dutasteride
                               4.3.2.1.1 Availability of generics post-patent expiry to support market growth
                               TABLE 24 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
                    4.3.2.2 Finasteride
                               4.3.2.2.1 Finasteride is less effective than alpha blockers in improving LUTS
                               TABLE 25 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.3.3 OTHER DRUG CLASSES
                    TABLE 26 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)
    4.4 PROSTATITIS
           TABLE 27 PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 28 PROSTATITIS MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.4.1 PRESCRIPTION PRODUCTS
                    4.4.1.1 Prescription drugs account for the larger share of the products used for the treatment of prostatitis
                               TABLE 29 PRESCRIPTION PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION)
           4.4.2 OVER-THE-COUNTER PRODUCTS
                    4.4.2.1 Sales of OTC products have risen over the past few years
                               TABLE 30 OVER-THE-COUNTER PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION)

5 PROSTATE HEALTH MARKET, BY REGION (Page No. - 51)
    5.1 INTRODUCTION
           TABLE 31 PROSTATE HEALTH MARKET, BY REGION, 2018–2026 (USD MILLION)
    5.2 NORTH AMERICA
           TABLE 32 NORTH AMERICA: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           TABLE 33 NORTH AMERICA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
           TABLE 34 NORTH AMERICA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 35 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
           TABLE 36 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 37 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 38 NORTH AMERICA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.2.1 US
                    5.2.1.1 The US holds the largest share of the North American market
                               TABLE 39 US: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 40 US: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 41 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 42 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 43 US: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 44 US: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.2.2 CANADA
                    5.2.2.1 Rising geriatric population and product approvals to support market growth
                               TABLE 45 CANADA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 46 CANADA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 47 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 48 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 49 CANADA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 50 CANADA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
    5.3 EUROPE
           TABLE 51 EUROPE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
           TABLE 52 EUROPE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 53 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
           TABLE 54 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 55 EUROPE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 56 EUROPE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 57 EUROPE: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           5.3.1 GERMANY
                    5.3.1.1 Increasing healthcare expenditure to support German market growth
                               TABLE 58 GERMANY: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 59 GERMANY: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 60 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 61 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 62 GERMANY: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 63 GERMANY: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                    5.3.2.1 Availability of innovative treatment options to drive the market in the UK
                               TABLE 64 UK: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 65 UK: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 66 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 67 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 68 UK: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 69 UK: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.3.3 FRANCE
                    5.3.3.1 Rising geriatric population to accelerate the growth of the market
                               TABLE 70 FRANCE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 71 FRANCE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 72 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 73 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 74 FRANCE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 75 FRANCE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.3.4 REST OF EUROPE
                    TABLE 76 ROE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                    TABLE 77 ROE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                    TABLE 78 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                    TABLE 79 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 80 ROE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 81 ROE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
    5.4 ASIA PACIFIC
           TABLE 82 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
           TABLE 83 ASIA PACIFIC: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 84 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
           TABLE 85 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 86 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
           TABLE 87 ASIA PACIFIC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           TABLE 88 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
           5.4.1 JAPAN
                    5.4.1.1 Japan holds the largest share of the APAC market
                               TABLE 89 JAPAN: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 90 JAPAN: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 91 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 92 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 93 JAPAN: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 94 JAPAN: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.4.2 CHINA
                    5.4.2.1 Increasing obese population to support market growth
                               TABLE 95 CHINA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 96 CHINA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 97 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 98 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 99 CHINA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 100 CHINA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
           5.4.3 INDIA
                    5.4.3.1 Rising prevalence of obesity to accelerate market growth in India
                               TABLE 101 INDIA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 102 INDIA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 103 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 104 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 105 INDIA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 106 INDIA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               5.4.4 REST OF ASIA PACIFIC
                               TABLE 107 ROAPAC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                               TABLE 108 ROAPAC: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                               TABLE 109 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                               TABLE 110 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 111 ROAPAC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                               TABLE 112 ROAPAC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
    5.5 LATIN AMERICA
           5.5.1 LATAM MARKETS DRIVEN BY GROWING PATIENT BASE
                    TABLE 113 LATAM: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                    TABLE 114 LATAM: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                    TABLE 115 LATAM: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                    TABLE 116 LATAM: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 117 LATAM: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 118 LATAM: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
    5.6 MIDDLE EAST AND AFRICA
           5.6.1 MEA COUNTRIES HOLD SMALLEST SHARE OF GLOBAL MARKET
                    TABLE 119 MEA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)
                    TABLE 120 MEA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
                    TABLE 121 MEA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
                    TABLE 122 MEA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 123 MEA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
                    TABLE 124 MEA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

6 COMPETITIVE LANDSCAPE (Page No. - 87)
    6.1 OVERVIEW
    6.2 REVENUE ANALYSIS OF BPH TREATMENT MARKET
           6.2.1 BPH MARKET REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS
                    FIGURE 8 TOP 5 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS
    6.3 REVENUE ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET
           6.3.1 PROSTATE CANCER THERAPEUTICS REVENUE ANALYSIS OF TOP 5 MARKET PLAYERS
                    FIGURE 9 TOP 4 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS
    6.4 MARKET SHARE ANALYSIS, 2020
           6.4.1 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2020
                    FIGURE 10 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2019
    6.5 COMPANY EVALUATION MATRIX
           6.5.1 STARS
           6.5.2 EMERGING LEADERS
           6.5.3 PERVASIVE COMPANIES
           6.5.4 PARTICIPANTS
                    FIGURE 11 PROSTATE HEALTH MARKET: COMPANY EVALUATION MATRIX, 2020

7 COMPANY PROFILES (Page No. - 92)
    7.1 GLAXOSMITHKLINE
    7.2 ASTELLAS PHARMA
    7.3 MERCK
    7.4 ELI LILLY AND COMPANY
    7.5 ABBOTT LABORATORIES
    7.6 JOHNSON & JOHNSON SERVICES, INC.
    7.7 ABBVIE
    7.8 ASTRAZENECA
    7.9 SANOFI
    7.10 PFIZER, INC.

8 APPENDIX (Page No. - 97)
    8.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
    8.2 AVAILABLE CUSTOMIZATIONS
    8.3 AUTHOR DETAILS

This study involved four major activities in estimating the size of the prostate health market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

This research study involved the use of widespread secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was mainly used to obtain key information about the industry’s total pool of key players, market classification and segmentation according to industry trends to the bottom-most segment level, global market trends, and key developments by public and private organizations. A database of the key industry leaders was also prepared using secondary research.

The secondary sources referred to for this research study include publications from government sources such as the Centers for Disease Control and Prevention, American Urological Association (AUA), National Health Service, European Association of Urology, US Food and Drug Administration, World Health Organization, Corporate Filings (such as annual reports, SEC filings, investor presentations, and financial statements), research journals, press releases, and trade, business, and professional associations.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report.

The primary sources from the supply side include CEOs, VPs, managing directors, marketing and sales heads/directors, marketing managers, regional/area sales managers, and prostate health scientists. Primary sources from the demand side include vice presidents, C-level executives, product managers, department heads, research scientists, research heads, and hospital directors. Other primary respondents include industry experts such as consultants, government, and officials/regulatory authorities.

Prostate Health Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the prostate health market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research.
  • The entire procedure included the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders, such as CEOs, VPs, directors, and marketing executives
  • All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources.
  • All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
  • This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Report Objectives

  • To define, describe, and forecast the prostate health market based disease indication and region
  • To provide detailed information regarding the major factors influencing the growth of this market (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall prostate health market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely,
    North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, collaborations, joint ventures, expansions, and acquisitions in the overall prostate health market
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product/service strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

  • Additional country-level analysis of prostate health market
  • Profiling of additional market players (up to 3)
Report Code
PH 8020
Published ON
Dec, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Prostate Health Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback